{"abstract":"The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent License to Inversago Pharma, Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/08/07/2018-16836.html","cfr_references":[],"citation":"83 FR 38707","comment_url":null,"comments_close_on":"2018-08-22","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development August 22, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-16836","effective_on":null,"end_page":38708,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/08/07/2018-16836.xml","html_url":"https://www.federalregister.gov/documents/2018/08/07/2018-16836/prospective-grant-of-exclusive-patent-license-treatment-of-type-i-diabetes-and-its-comorbidities","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-16836?publication_date=2018-08-07","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-08-07/2018-16836/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":202,"last_updated":"2026-06-24 02:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-08-07/pdf/2018-16836.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-16836.pdf?1533559524","publication_date":"2018-08-07","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/08/07/2018-16836.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T08:07:07Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":38707,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Treatment of Type I Diabetes and its Comorbidities","toc_doc":"Treatment of Type I Diabetes and its Comorbidities","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":83}